Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Arena Falters on Belviq EU Approval – Analyst Blog

Arena Pharmaceuticals Inc. (ARNA) recently received ‘The Day 180 List of Outstanding Issues’ from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), in relation to its weight loss drug, Belviq. Arena’s shares were down significantly (almost 10%) on the news.

Arena needs to discuss the issues with the CHMP before the latter gives its final opinion on the marketing approval of Belviq. The issues are both non-clinical and clinical in nature, including tumors in rats, valvulopathy and psychiatric events. The company has been asked to justify Belviq’s overall risk-benefit profile after considering the above issues.

Arena had filed a Marketing Authorization Application (MAA) to the EMA for Belviq in Mar 2012. The company is looking to get the product approved as an adjunct to diet and exercise for weight control in overweight adults. The final opinion from the CHMP regarding Belviq is expected in the first half of this year.

We remind investors that another obesity drug, Vivus Inc.’s (VVUS) Qsiva, also received a negative opinion from the CHMP in Oct 2012. The CHMP rendered a negative opinion due to concerns over the potential cardiovascular and central nervous system effects associated with the long-term use, teratogenic potential and use by patients for whom Qsiva is not meant.

We expect investor focus to remain on the final opinion of the CHMP on EU approval of Belviq.

We currently have a Zacks Rank #2 (Buy) on the stock. Alkermes (ALKS) and Medivation Inc. (MDVN), carrying a Zacks Rank #1 (Strong Buy), currently appear to be more attractive in the pharma space.
ALKERMES INC (ALKS): Free Stock Analysis Report

ARENA PHARMA (ARNA): Free Stock Analysis Report

MEDIVATION INC (MDVN): Free Stock Analysis Report

VIVUS INC (VVUS): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

Join the conversation. Click here to jump to comments…

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK